Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Bram Slütter

Showing results (1-10 of 83) with videos related to

Pageof 9
Sort By:
Journal of Controlled Release : Official Journal of the Controlled Release Society|July 6, 2010
Dual role of CpG as immune modulator and physical crosslinker in ovalbumin loaded N-trimethyl chitosan (TMC) nanoparticles for nasal vaccinationBram Slütter, Wim Jiskoot
Circulation|May 29, 2019
Immune Responses in ContextBram Slütter, Johan Kuiper
Cardiovascular Research|February 10, 2026
Empowering regulatory T cells to restore immune tolerance and reduce inflammation-driven atherosclerosisFabrizia Bonacina, Bram Slütter
Expert Opinion on Drug Delivery|November 19, 2015
Sizing the optimal dimensions of a vaccine delivery system: a particulate matterBram Slütter, Wim Jiskoot
Frontiers in Immunology|July 5, 2024
Editorial: Adaptive immunity in atherosclerosisBram Slütter, Klaus Ley
Cell Host & Microbe|October 10, 2014
Instructing the instructor: tissue-resident T cells activate innate immunityBram Slütter, John T Harty
Journal of Drug Targeting|January 4, 2008
Rational design of nasal vaccinesBram Slütter, Niels Hagenaars, Wim Jiskoot
Current Opinion in Lipidology|July 19, 2018
The many faces of CD8+ T cells in atherosclerosisJanine van Duijn, Johan Kuiper, Bram Slütter
Ebiomedicine|June 24, 2020
Tolerogenic vaccines for the treatment of cardiovascular diseasesFernando Lozano Vigario, Johan Kuiper, Bram Slütter
Current Opinion in Biotechnology|December 28, 2023
Biological recognition and cellular trafficking of targeted RNA-lipid nanoparticlesOscar Escalona-Rayo, Panagiota Papadopoulou, Bram Slütter, et al.
Pageof 9

Showing results (1-10 of 83) with videos related to

Sort By:
Pageof 9
Journal of Controlled Release : Official Journal of the Controlled Release Society|July 6, 2010
Dual role of CpG as immune modulator and physical crosslinker in ovalbumin loaded N-trimethyl chitosan (TMC) nanoparticles for nasal vaccinationBram Slütter, Wim Jiskoot
Circulation|May 29, 2019
Immune Responses in ContextBram Slütter, Johan Kuiper
Cardiovascular Research|February 10, 2026
Empowering regulatory T cells to restore immune tolerance and reduce inflammation-driven atherosclerosisFabrizia Bonacina, Bram Slütter
Expert Opinion on Drug Delivery|November 19, 2015
Sizing the optimal dimensions of a vaccine delivery system: a particulate matterBram Slütter, Wim Jiskoot
Frontiers in Immunology|July 5, 2024
Editorial: Adaptive immunity in atherosclerosisBram Slütter, Klaus Ley
Cell Host & Microbe|October 10, 2014
Instructing the instructor: tissue-resident T cells activate innate immunityBram Slütter, John T Harty
Journal of Drug Targeting|January 4, 2008
Rational design of nasal vaccinesBram Slütter, Niels Hagenaars, Wim Jiskoot
Current Opinion in Lipidology|July 19, 2018
The many faces of CD8+ T cells in atherosclerosisJanine van Duijn, Johan Kuiper, Bram Slütter
Ebiomedicine|June 24, 2020
Tolerogenic vaccines for the treatment of cardiovascular diseasesFernando Lozano Vigario, Johan Kuiper, Bram Slütter
Current Opinion in Biotechnology|December 28, 2023
Biological recognition and cellular trafficking of targeted RNA-lipid nanoparticlesOscar Escalona-Rayo, Panagiota Papadopoulou, Bram Slütter, et al.
Pageof 9